Nitin Patel, MD
Psychiatry · Valdosta, GANPI 1770511156
Payments from drug & device makers
Across 147 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$468
- Axsome Therapeutics, Inc.$376
- Vanda Pharmaceuticals Inc.$320
- Otsuka America Pharmaceutical, Inc.$248
- Takeda Pharmaceuticals U.S.A., Inc.$219
- Ironshore Pharmaceuticals Inc.$185
- plus $1K from 17 others
What the payments were for
- Food & beverage$2,897100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 41 | $468 |
| Axsome Therapeutics, Inc. | 14 | $376 |
| Vanda Pharmaceuticals Inc. | 12 | $320 |
| Otsuka America Pharmaceutical, Inc. | 12 | $248 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $219 |
| Ironshore Pharmaceuticals Inc. | 8 | $185 |
| Johnson & Johnson | 5 | $156 |
| Teva Pharmaceuticals USA, Inc. | 6 | $154 |
| Bausch Health US, LLC | 6 | $120 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $93 |
| Almatica Pharma LLC | 5 | $83 |
| Lundbeck LLC | 4 | $80 |
| E.r. Squibb & Sons, L.L.C. | 1 | $79 |
| Alkermes, Inc. | 3 | $55 |
| Neurocrine Biosciences, Inc. | 2 | $52 |
| Shire North American Group Inc | 3 | $49 |
| Corium, LLC | 1 | $31 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| Nevro Corp. | 1 | $29 |
| Alfasigma USA, Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Noven Therapeutics, LLC | 1 | $17 |
| Kls-martin L.p. | 1 | $10 |
How this compares
$2,897 in reported general payments places this provider in the 80th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 22 | $29,152 |
| TrintellixVortioxetine Hydrobromide | 24 | $11,513 |
| BelsomraSuvorexant | 14 | $6,140 |
| LexaproEscitalopram Oxalate | 13 | $5,220 |
| Fluoxetine Hcl | 37 | $4,326 |
| Duloxetine Hcl | 259 | $3,813 |
| Aripiprazole | 205 | $3,518 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 232 | $2,740 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 47 | $2,670 |
| Ziprasidone Hcl | 34 | $2,148 |
| Buspirone Hcl | 139 | $2,047 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 39 | $1,901 |
| Bupropion XlBupropion Hcl | 199 | $1,867 |
| Alprazolam | 274 | $1,472 |
| Paroxetine ErParoxetine Hcl | 11 | $1,312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Lexapro | $468 | $34,37135 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $219 | $11,51324 claims |
| Almatica Pharma LLCSertraline Hcl | $83 | $1,254242 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Valdosta
- Joel MorganValdosta$337K
- Robert RiesenbergAtlanta$51.1M
- Saundra Maass-RobinsonAtlanta$11.1M
- David PurselleAtlanta$7.4M
- Maria JohnsonDecatur$5.4M
- Bethany DavisAtlanta$4.4M
- Michael BanovMarietta$4.2M
- Michael MobleySavannah$2.9M
- Richard PettyLoganville$2.9M
- Felipe SuplicyRome$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.